
CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cdc7-IN-1
CAS:<p>Cdc7-IN-1: selective ATP-competitive Cdc7 kinase inhibitor; IC50 0.6 nM at 1mM ATP; induces cancer cell death.</p>Formula:C21H16ClN3O4Color and Shape:SolidMolecular weight:409.82CDK9-IN-14
CAS:<p>CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.</p>Formula:C21H23F2N3O4Color and Shape:SolidMolecular weight:419.42CLK1/2-IN-3
CAS:<p>CLK1/2-IN-3 (Cpd-3) is a CLK1 and CLK2 inhibitor with antiproliferative activity that inhibits the activity of CLK and SRPK.</p>Formula:C21H21N5O2Purity:99.04%Color and Shape:SolidMolecular weight:375.42THZ1-R
CAS:<p>THZ1-R is a non-covalent active analogue of THZ1, with the acrylamide group removed from THZ1, not covalently bind to the C312 cysteine residue of CDK7.</p>Formula:C31H30ClN7O2Purity:98%Color and Shape:SolidMolecular weight:568.07CLK1-IN-1
CAS:<p>CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).</p>Formula:C24H16FN5OColor and Shape:SolidMolecular weight:409.42CDK12-IN-E9
CAS:<p>CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux.</p>Formula:C24H30N6O2Color and Shape:SolidMolecular weight:434.53Cdc7-IN-17
CAS:<p>Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].</p>Formula:C13H15N5OSColor and Shape:SolidMolecular weight:289.36AS2863619 free base
CAS:<p>AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells.</p>Formula:C16H12N8OColor and Shape:SolidMolecular weight:332.32Cdc7-IN-4
CAS:<p>Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.</p>Formula:C22H24F3N5O4Purity:98%Color and Shape:SolidMolecular weight:479.45K 00546
CAS:<p>K00546 inhibits CDK1/cyclin B (IC50: 0.6 nM), CDK2/cyclin A (IC50: 0.5 nM), CLK1 (IC50: 8.9 nM), and CLK3 (IC50: 29.2 nM).</p>Formula:C15H13F2N7O2S2Purity:99.12%Color and Shape:SolidMolecular weight:425.44CDK8-IN-7
CAS:<p>CDK8-IN-7 is a potent CDK8 inhibitor with a Kd of 3.5 nM, showing promise for AML research.</p>Formula:C30H40N2Color and Shape:SolidMolecular weight:428.65Cdc7-IN-15
CAS:<p>Cdc7-IN-15 (Example 108) is an inhibitor of cdc7 kinase that has potential to be used for cancer research [1].</p>Formula:C12H14N4OSColor and Shape:SolidMolecular weight:262.33CP681301
CAS:<p>CP681301 is a potent CDK5 inhibitor with anti-tumor effects in Drosophila and reduces Glioma stem cells' growth and renewal.</p>Formula:C17H22N4OColor and Shape:SolidMolecular weight:298.38MDK6204
CAS:<p>MDK6204 is a selective inhibitor of CLK1 and CLK2.</p>Formula:C20H20N6OPurity:98%Color and Shape:SolidMolecular weight:360.41BSJ-01-175
CAS:<p>BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.</p>Formula:C30H33ClN6O2Color and Shape:SolidMolecular weight:545.08Indirubin-3'-monoxime-5-sulphonic acid
CAS:<p>Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.</p>Formula:C16H11N3O5SPurity:98%Color and Shape:SolidMolecular weight:357.34CDK7-IN-13
CAS:<p>CDK7-IN-13: A potent pyrimidine-based CDK7 inhibitor, potential for various cancers. See CN114249712A.</p>Formula:C20H23F3N6OSPurity:99.22%Color and Shape:SolidMolecular weight:452.5P18IN003
CAS:<p>P18IN003 is a selective and effective p18(INK4C) inhibitor that inhibits the activity of p18 protein and can be used to study in vitro expansion of</p>Formula:C17H16N2O3Purity:98.77%Color and Shape:SolidMolecular weight:296.32CDK7-IN-20
<p>CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.</p>Formula:C30H26N6O3Color and Shape:SolidMolecular weight:518.57FLT3/CDK4-IN-1
CAS:<p>FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.</p>Formula:C25H28F2N8Color and Shape:SolidMolecular weight:478.54BS-181
CAS:<p>BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.</p>Formula:C22H32N6Purity:98%Color and Shape:SolidMolecular weight:380.53CDK4/6-IN-12
CAS:<p>CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.</p>Formula:C12H10N6Color and Shape:SolidMolecular weight:238.25CGP60474
CAS:<p>CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.</p>Formula:C18H18ClN5OPurity:98.81%Color and Shape:SolidMolecular weight:355.82CCT068127
CAS:<p>CCT068127 is a potent CDK2 and CDK9 inhibitor.</p>Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.46(S)-CR8
CAS:<p>(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.</p>Formula:C24H29N7OColor and Shape:SolidMolecular weight:431.53CDK7-IN-8
CAS:<p>CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.</p>Formula:C25H38N8O3Color and Shape:SolidMolecular weight:498.62EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Formula:C24H21N3O4S2Color and Shape:SolidMolecular weight:479.57Aloisine A
CAS:<p>Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.</p>Formula:C16H17N3OPurity:98%Color and Shape:SolidMolecular weight:267.33TP1287
CAS:<p>TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.</p>Formula:C21H21ClNO8PColor and Shape:SolidMolecular weight:481.82Indirubin-5-sulfonate
CAS:<p>Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.</p>Formula:C16H10N2O5SPurity:98%Color and Shape:SolidMolecular weight:342.33Crozbaciclib fumarate
CAS:<p>Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.</p>Formula:C32H34F2N6O4Color and Shape:SolidMolecular weight:604.65CDK7-IN-12
CAS:<p>CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.</p>Formula:C20H19F3N6Color and Shape:SolidMolecular weight:400.4CDK1-IN-1
CAS:<p>CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.</p>Formula:C27H23N5O3Color and Shape:SolidMolecular weight:465.5CDK4/6-IN-9
CAS:<p>CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.</p>Formula:C22H23FN8Color and Shape:SolidMolecular weight:418.47Cdc7-IN-13
CAS:<p>Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].</p>Formula:C18H20N4O2SColor and Shape:SolidMolecular weight:356.44Ulecaciclib
CAS:<p>Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).</p>Formula:C25H33FN8SColor and Shape:SolidMolecular weight:496.65FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Formula:C22H25N9OPurity:97.4%Color and Shape:SolidMolecular weight:431.49JTK-101
CAS:<p>JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.</p>Formula:C25H23N3O3Color and Shape:SolidMolecular weight:413.47(E/Z)-BIO-acetoxime
CAS:<p>(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.</p>Formula:C18H12BrN3O3Color and Shape:SolidMolecular weight:398.21(S)-LY3177833 hydrate
CAS:<p>(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.</p>Formula:C16H14FN5O2Color and Shape:SolidMolecular weight:327.31RP-106
CAS:<p>RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.</p>Formula:C17H19N3OPurity:98%Color and Shape:SolidMolecular weight:281.35PKC-9
CAS:<p>PKC-9 is a PKC-zeta inhibitor 9.</p>Formula:C25H25N7Color and Shape:SolidMolecular weight:423.51CDK4/6-IN-7
CAS:<p>CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.</p>Formula:C18H18ClN5O3Color and Shape:SolidMolecular weight:387.82Cdc7-IN-3
CAS:<p>Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.</p>Formula:C20H22N4O5Purity:98%Color and Shape:SolidMolecular weight:398.41CDK7-IN-2
CAS:<p>CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.</p>Formula:C26H39N7O3Color and Shape:SolidMolecular weight:497.63EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Formula:C23H21N3O3S2Color and Shape:SolidMolecular weight:451.56CDK5 inhibitor 20-223
CAS:<p>CDK5 inhibitor 20-223 is a potent CDK2/CDK5 inhibitor,anti-Colorectal Cancer (CRC), inhibiting cell migration and inducing cell cycle arrest.</p>Formula:C19H19N3OColor and Shape:SolidMolecular weight:305.37FN-1501-propionic acid
CAS:<p>FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.</p>Formula:C25H27N9O4Purity:98%Color and Shape:SolidMolecular weight:517.54EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Formula:C23H20N4O5S2Color and Shape:SolidMolecular weight:496.56CDK8-IN-10
CAS:<p>CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.</p>Formula:C25H15ClF3N5O3Color and Shape:SolidMolecular weight:525.87CDK4/6-IN-8
CAS:<p>CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).</p>Formula:C18H18N6O5Color and Shape:SolidMolecular weight:398.37AS-0141
CAS:<p>AS-0141 (Cdc7-IN-6) 是一种有效的 Cdc7 激酶抑制剂 (IC50=4 nM),具有抗肿瘤活性。Cdc7 是一种丝氨酸苏氨酸蛋白激酶酶,在细胞周期中对 DNA 复制的启动至关重要。</p>Formula:C21H22F3N5O4Purity:99.97%Color and Shape:SolidMolecular weight:465.43Ryuvidine
CAS:<p>Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.</p>Formula:C15H12N2O2SPurity:98.6%Color and Shape:SolidMolecular weight:284.33(S)-Enitociclib
CAS:<p>(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that inhibits the transcription of anti-apoptotic and pro-survival proteins.</p>Formula:C19H18F2N4O2SPurity:98.98%Color and Shape:SolidMolecular weight:404.43CLK-IN-T3
CAS:<p>CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.</p>Formula:C28H30N6O2Purity:99.61%Color and Shape:SolidMolecular weight:482.58(S)-PF-06873600
CAS:<p>(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.</p>Formula:C20H27F2N5O4SPurity:98.59%Color and Shape:SolidMolecular weight:471.52CDK9-IN-10
CAS:<p>CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.</p>Formula:C22H16O5Purity:99.8%Color and Shape:SolidMolecular weight:360.36PS423
CAS:<p>PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.</p>Formula:C25H23F3O9Purity:98.81% - 99.26%Color and Shape:SolidMolecular weight:524.44HTH-01-091
CAS:<p>HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM).HTH-01-091 inhibits PIM1/2/3, RIPK2, DYRK3,</p>Formula:C26H28Cl2N4O2Purity:98.4%Color and Shape:SolidMolecular weight:499.43hSMG-1 inhibitor 11e
CAS:<p>hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.</p>Formula:C26H27N7O3SPurity:99.89%Color and Shape:SolidMolecular weight:517.6CDK-IN-2
CAS:<p>CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).</p>Formula:C18H19ClFN3O2Purity:99.67%Color and Shape:SolidMolecular weight:363.819-Isopropylolomoucine
CAS:<p>9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.</p>Formula:C17H22N6OPurity:99.82%Color and Shape:SolidMolecular weight:326.4CDK8-IN-1
CAS:<p>CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).</p>Formula:C11H8F3N3OPurity:98.48%Color and Shape:SolidMolecular weight:255.2Cdc7-IN-7c
CAS:<p>Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.</p>Formula:C15H17N5OSPurity:98.19% - 99.22%Color and Shape:SolidMolecular weight:315.39SEL120-34A
CAS:<p>SEL120-34A inhibits CDK8 (IC50: 4.4 nM) & CDK19 (10.4 nM), less on CDK9 (1070 nM), has antitumor properties.</p>Formula:C15H18Br2N4Purity:99.764% - 99.84%Color and Shape:SolidMolecular weight:414.14CDK4/6/1 Inhibitor
CAS:<p>CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).</p>Formula:C28H30F2N6Purity:99.26% - 99.72%Color and Shape:SolidMolecular weight:488.57BML-259
CAS:<p>BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.</p>Formula:C14H16N2OSPurity:99.84%Color and Shape:SolidMolecular weight:260.35dCeMM2
CAS:<p>dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.</p>Formula:C16H11ClN6OSPurity:99.68%Color and Shape:SolidMolecular weight:370.82Cdk2 Inhibitor II
CAS:<p>Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.</p>Formula:C14H11BrN4O3SPurity:97.07%Color and Shape:SolidMolecular weight:395.23Abemaciclib metabolite M20
CAS:<p>Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂,可用于癌症治疗的相关研究。</p>Formula:C27H32F2N8OPurity:98.1% - 99.08%Color and Shape:SolidMolecular weight:522.59SHP2/CDK4-IN-1
CAS:<p>SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.</p>Formula:C33H35ClF2N10OSColor and Shape:SolidMolecular weight:693.21CDK-IN-11
CAS:<p>CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].</p>Formula:C25H21BrN4O2Color and Shape:SolidMolecular weight:489.36CDK/HDAC-IN-3
CAS:<p>CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,</p>Formula:C24H18Cl2N6O3Purity:98%Color and Shape:SolidMolecular weight:509.34Cdk4 Inhibitor
CAS:<p>PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.</p>Formula:C20H10BrN3O2Color and Shape:SolidMolecular weight:404.2EHT 5372
CAS:<p>EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.</p>Formula:C17H11Cl2N5OSColor and Shape:SolidMolecular weight:404.27Nε-(1-Carboxyethyl)-L-lysine
CAS:<p>Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.</p>Formula:C9H18N2O4Color and Shape:SolidMolecular weight:218.25Lerociclib
CAS:<p>Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.</p>Formula:C26H34N8OPurity:99%Color and Shape:SolidMolecular weight:474.6CDK8-IN-3
CAS:<p>CDK8-IN-3 is an inhibitor of CDK8.</p>Formula:C22H23N5O2Purity:98%Color and Shape:SolidMolecular weight:389.45CDK9-IN-29
CAS:<p>CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.</p>Formula:C29H33F2N5O4Purity:98%Color and Shape:SolidMolecular weight:553.6IIIM-290
CAS:<p>IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).</p>Formula:C23H21Cl2NO5Purity:98%Color and Shape:SolidMolecular weight:462.32CCT-251921
CAS:<p>CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).</p>Formula:C21H23ClN6OPurity:99.07%Color and Shape:SolidMolecular weight:410.9CDK9-IN-8
CAS:<p>CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).</p>Formula:C31H32FN7O3Purity:99.54%Color and Shape:SolidMolecular weight:569.63QR-6401
CAS:<p>QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/</p>Formula:C19H23N5O3Purity:98%Color and Shape:SolidMolecular weight:369.42Tacaciclib
CAS:<p>Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].</p>Formula:C30H36N6O3Purity:98%Color and Shape:SolidMolecular weight:528.65Mevociclib
CAS:<p>Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.</p>Formula:C31H35ClN8O2Purity:98.02% - 98.02%Color and Shape:SolidMolecular weight:587.11Palbociclib orotate
CAS:<p>Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.</p>Formula:C29H33N9O6Purity:98%Color and Shape:SolidMolecular weight:603.63KM05382
CAS:<p>KM05382 inhibits CDK9 and the transcription of GAPDH.</p>Formula:C20H19ClN2O3S2Color and Shape:SolidMolecular weight:434.96CDK4-IN-2
CAS:<p>CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].</p>Formula:C22H26F2N6O4SPurity:98%Color and Shape:SolidMolecular weight:508.54DCB-3503
CAS:<p>DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.</p>Formula:C24H27NO5Color and Shape:SolidMolecular weight:409.47LDC3140
CAS:<p>LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).</p>Formula:C23H33N7OPurity:98%Color and Shape:SolidMolecular weight:423.55Leucettinib-92
CAS:<p>Leucettinib-92 (compound 92) is a kinase inhibitor selective for DYRK/CLK families, displaying IC50 values of 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM</p>Formula:C21H22N4OSPurity:98%Color and Shape:SolidMolecular weight:378.49CDK9-IN-9
CAS:<p>CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).</p>Formula:C22H23F2N5O2SPurity:98%Color and Shape:SolidMolecular weight:459.51(2S,3R)-Voruciclib
CAS:<p>(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.</p>Formula:C22H19ClF3NO5Purity:98%Color and Shape:SolidMolecular weight:469.84CDK9-IN-2
CAS:<p>CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.</p>Formula:C23H25ClFN5Purity:99%Color and Shape:SolidMolecular weight:425.93CDK7-IN-14
CAS:<p>CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).</p>Formula:C22H24F3N6OPColor and Shape:SolidMolecular weight:476.435-Iodo-indirubin-3'-monoxime
CAS:<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Formula:C16H10IN3O2Color and Shape:SolidMolecular weight:403.17NU6300
CAS:<p>NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.</p>Formula:C20H23N5O3SPurity:96.08%Color and Shape:SolidMolecular weight:413.49Voruciclib hydrochloride
CAS:<p>Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).</p>Formula:C22H20Cl2F3NO5Purity:98%Color and Shape:SolidMolecular weight:506.3PF-6808472
CAS:<p>PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.</p>Formula:C25H27FN8O3SPurity:99.02%Color and Shape:SolidMolecular weight:538.6CDK7-IN-22
CAS:<p>CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].</p>Formula:C22H25F3N6Purity:98%Color and Shape:SolidMolecular weight:430.47

